TagsHematology 
The Ever-Changing Landscape of Unresectable Hepatocellular Carcinoma

Paradigm Shift in Management of Unresectable Hepatocellular Carcinoma (uHCC) In Hong Kong, liver cancer is the fifth most common cancer (with 1,771 new cases of liver cancer reported in 2021) and the third most common cause of cancer-related deaths ...

Apr 18, 2024
The New All-Oral Fixed-duration Regimen for Young and Fit Chronic Lymphocytic Leukaemia Patients

Chronic Lymphocytic Leukaemia (CLL) is a lymphoproliferative disorder characterised by the expansion of monoclonal, mature CD5+ CD23+ B cells in the peripheral blood, secondary lymphoid tissues, and bone marrow 1 . The molecular heterogeneity of CLL...

Oct 26, 2023
Management of Relapsed or Refractory Multiple Myeloma

Principles for Treatment Selection The newly established European guidelines advocate IMiD-based therapies as the induction therapy for patients with newly diagnosed multiple myeloma (NDMM), regardless of eligibility for autologous stem cell transpl...

Mar 18, 2022
Hybrid Lecture on Management of Relapsed or Refractory Multiple Myeloma

The management of relapsed and refractory multiple myeloma (RRMM) continues to be challenging though new therapeutics for the disease have been emerging in recent decades. Essentially, while decreased survival was observed in each extra line of ther...

Mar 17, 2022
Proven Benefits of IMiDs-based Regimen in Managing Multiple Myeloma

Currently Available Therapeutic Options for MM MM is currently one of the most prevalent haematological malignancies, which mainly affects individuals aged above 65 2 , a relatively vulnerable group of patients owing to comorbidities and immunosenes...

Dec 20, 2021
Therapeutic Sequencing Strategy in Multiple Myeloma

The Multitude of Activities of IMiDs Because of the established benefits, IMiDs are recommended as induction therapy for both transplant eligible and ineligible patients, in the post-transplant maintenance setting, and for relapsed/refractory diseas...

Dec 20, 2021
Pomalidomide in Lenalidomide-refractory Multiple Myeloma

Background Information The patient of the current case was a 64-year-old male with documented ischemic heart disease and received 3 times of percutaneous coronary intervention (PCI), respectively in 2004, 2005 and 2013. In 2015, the patient complain...

Dec 20, 2021
Unmet Needs in Relapsed and Refractory Multiple Myeloma

Reduced Overall Survival in Refractory MM Although the application of the first IMiD, lenalidomide, had significantly increased median overall survival (OS) 2 , Prof. Leleu commented that the treatment success was hindered by the refractoriness of M...

Sep 20, 2021
Webinar on Therapeutic Sequencing Strategy in Multiple Myeloma

Therapeutic Sequencing Strategy in Multiple Myeloma Date: 24 th June 2021 (Thursday) Time: 19:00 - 20:40 (GMT+8, HKT) Meeting format: Zoom meeting Address: Salon Room III, Hyatt Regency Hong Kong, 18 Hanoi Road, Tsim Sha Tsui, Kowloon The survival o...

Sep 20, 2021
Webinar on Unmet Needs in Relapsed and Refractory Multiple Myeloma

Over the past 25 years, significant progress has been made in the treatment of multiple myeloma (MM) as reflected by the improved overall survival (OS). However, in relapsed and refractory MM (RRMM), median OS decreases with each extra line of thera...

Jun 21, 2021
Treatment of Multiple Myeloma: The Role of Immunomodulatory Drugs

T he Importance of Achieving Deepest Possible Response and Continuous Therapy While improving long-term survival for patients with MM is desirable, clinical data suggested that complete response (CR) to treatment is associated with survival outcomes...

Jun 21, 2021
Management of Relapsed and Refractory Multiple Myeloma

Management of Relapsed and Refractory Multiple Myeloma Date: 25 February 2021 (Thursday) Time: 19:15 - 20:40 (GMT+8, HKT) Meeting format: Zoom meeting Webinar on Management of Relapsed and Refractory Multiple Myeloma Multiple myeloma (MM) is charact...

Mar 16, 2021